Regorafenib-nublexa (40 mg): Check Drug Details and Specifications

Indication

Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild- type, an anti-EGFR therapy. It is also use to treat metastaticgastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

Note

Precaution

• Nublexa is a prescription drug and should be used under proper medical guidance and advice.
• Control hypertension before initiating treatment; monitor blood pressure regularly during treatment.
• Advise females & males of reproductive potential to use effective contraception during treatment and for 2 months after final dose.
• Increases risk for hemorrhage; discontinue therapy for severe or life-threatening hemorrhage.